Fundraising Fox
Cardurion Pharmaceuticals
Burlington, US · Founded 2017 · 74 employees on LinkedIn · 15 known investors
Find your way into Cardurion Pharmaceuticals
Sign up to see every warm intro you have to Cardurion Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cardurion Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
Founders & leadership
Cardurion Pharmaceuticals was founded in 2017 by Michael E. Mendelsohn.
Board
Investors · 15
How we know: the company's own site · funding news · Not right? Tell us
How we know: Ascenta Capital's portfolio page · finance.yahoo.com · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · finance.yahoo.com · Not right? Tell us
How we know: DeepWork Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Delos Capital's portfolio page · press coverage · Not right? Tell us
How we know: Digitalis Ventures's portfolio page · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · a partner's Signal profile · finance.yahoo.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · finance.yahoo.com · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$260M disclosed across 1 of 2 rounds · 2024
- $260MSeries BJul 2024 · 3 sources
Ascenta Capital (lead), Bain, Bain Capital Life Sciences, GV, NEA
Source ↗
▶$260.4MraisedJul 2024 · 19 investors · BiotechnologyRule 506(b)
- Evan RachlinDirector
- Jeb KeiperDirector
- Michael MendelsohnExecutive Officer, Director
- Daniel LynchDirector
- Emma ReeveDirector
- Peter LawrenceExecutive Officer, Director
- Edward MathersDirector
- Adam KoppelDirector
- Nicholas DowningDirector
- Offering amount
- $260.4M
- Amount sold
- $260.4M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$128.1MraisedJul 2023 · 2 investors · BiotechnologyRule 506(b)
- Adam KoppelDirector
- Keith GottesdienerDirector
- Kenneth NovackDirector
- Jeb KeiperDirector
- Nicholas DowningDirector
- Michael MendelsohnExecutive Officer, Director
- Peter LawrenceExecutive Officer, Director
- Offering amount
- $128.1M
- Amount sold
- $128.1M
- Finders' fees
- $3.1M
- Placement agents
- SVB Leerink LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17.5MraisedDec 2022 · 2 investors · BiotechnologyRule 506(b)
- Adam KoppelDirector
- Kenneth NovackDirector
- Amy SchulmanDirector
- Peter LawrenceExecutive Officer, Director
- Nicholas DowningDirector
- Jeb KeiperDirector
- Michael MendelsohnExecutive Officer, Director
- Keith GottesdienerDirector
- Offering amount
- $17.5M
- Amount sold
- $17.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$10MraisedNov 2019 · 2 investors · BiotechnologyRule 506(b)
- Jeb KeiperDirector
- Amy SchulmanDirector
- Kenneth NovackDirector
- Michael MendelsohnExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.7MraisedApr 2017 · 1 investors · BiotechnologyRule 506(b)
- Michael MendelsohnExecutive Officer, Director
- Offering amount
- $22.4M
- Amount sold
- $15.7M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Georgia, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cardurion Pharmaceuticals do?
- Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
- Who founded Cardurion Pharmaceuticals?
- Cardurion Pharmaceuticals was founded by Michael E. Mendelsohn in 2017.
- Who are Cardurion Pharmaceuticals's investors?
- Cardurion Pharmaceuticals's investors include Bain Capital, Ascenta Capital, Bain Capital Life Sciences, DeepWork Capital, Delos Capital, Digitalis Ventures, GV (Google Ventures), New Enterprise Associates (NEA) and 6 more.
- How much funding has Cardurion Pharmaceuticals raised?
- Cardurion Pharmaceuticals has disclosed $260M raised across 1 of its 2 known rounds.
- Where is Cardurion Pharmaceuticals headquartered?
- Cardurion Pharmaceuticals is headquartered in Burlington, US.